These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2528599)

  • 1. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1007-14. PubMed ID: 2528599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
    Shimizu Y; Fujiwara H; Ueda S; Wakamiya N; Kato S; Hamaoka T
    Eur J Immunol; 1984 Sep; 14(9):839-43. PubMed ID: 6236991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
    J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of tumor-bearing mice utilizing virus help.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Cancer Immunol Immunother; 1988; 27(3):223-7. PubMed ID: 3263207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Shimizu Y; Takai Y; Wakamiya N; Ueda S; Kato S; Hamaoka T
    Eur J Immunol; 1984 Feb; 14(2):171-5. PubMed ID: 6199215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of two kinds of tumor vaccine modified with vaccinia virus.
    Ito T; Okabayashi M; Osada Y; Wakamiya N; Kato S
    In Vivo; 1988; 2(5):325-9. PubMed ID: 2979853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
    Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T
    Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells.
    Sato S; Fukuzawa M; Nakajima H; Ogata M; Kosugi A; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1985 Nov; 76(11):1099-106. PubMed ID: 2935516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K; Hamaoka T; Tominaga A; Kanamasa Y
    J Immunol; 1980 Dec; 125(6):2367-73. PubMed ID: 6776192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
    Schmid DS; Rouse BT
    J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor-specific immunotherapy model utilizing virus-reactive helper T-cell activities].
    Shimizu Y; Nakayama K; Hirai Y; Chen JT; Hamada T; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K; Okudaira Y
    Nihon Gan Chiryo Gakkai Shi; 1988 Jun; 23(6):1307-14. PubMed ID: 2976420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.